BRONCHIOLITIS OBLITERANS SYNDROME
Clinical trials for BRONCHIOLITIS OBLITERANS SYNDROME explained in plain language.
Never miss a new study
Get alerted when new BRONCHIOLITIS OBLITERANS SYNDROME trials appear
Sign up with your email to follow new studies for BRONCHIOLITIS OBLITERANS SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug may help lung damage after stem cell transplants
Disease control OngoingThis study tests a new oral drug called alvelestat (MPH966) in adults who have lung damage (bronchiolitis obliterans syndrome) after a stem cell transplant. The drug aims to block an enzyme that may cause lung injury. The trial has two parts: first to find the safest and most eff…
Matched conditions: BRONCHIOLITIS OBLITERANS SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a cancer drug help lung damage after transplant?
Disease control OngoingThis phase 2 study tests the drug ruxolitinib (Jakafi) in 50 people who developed bronchiolitis obliterans syndrome (BOS) after a stem cell transplant. BOS is a serious lung condition that causes scarring and breathing problems. The goal is to see if ruxolitinib can improve lung …
Matched conditions: BRONCHIOLITIS OBLITERANS SYNDROME
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC